- Home
- BHV vs SKYE Comparison
BHV vs SKYE Comparison
Compare BHV & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BHV | SKYE |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.9M | 20.0M |
| IPO Year | 2002 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BHV | SKYE |
|---|---|---|
| Price | $12.49 | $1.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 2.3K | ★ 549.5K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.04 | $0.26 |
| 52 Week High | $13.30 | $4.99 |
Technical Indicators
Market Signals| Indicator | BHV | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 50.47 | 68.63 |
| Support Level | $12.50 | $0.66 |
| Resistance Level | $13.00 | $2.32 |
| Average True Range (ATR) | 0.20 | 0.15 |
| MACD | -0.01 | 0.09 |
| Stochastic Oscillator | 32.46 | 74.33 |
Price Performance
Historical ComparisonAbout BHV BlackRock Virginia Municipal Bond Trust
Blackrock Virginia Municipal Bond Trust is a perpetual closed-end municipal bond fund. Its objective is to provide current income exempt from regular Federal income taxes and Virginia personal income taxes.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.